Research from George Mason University in the Area of Adenocarcinoma Described (Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma).

A research study conducted by George Mason University has found that keratin 17 (K17) can serve as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma (PDAC). The study analyzed the expression of K17 in PDAC samples and determined a threshold of expression that could optimize prognostic stratification. The results showed that patients with low K17 PDACs treated with 5-fluorouracil (5-FU)-based chemotherapy had significantly longer survival compared to those treated with gemcitabine-based chemotherapy. The study suggests that K17 could be used to optimize therapeutic interventions for PDAC patients. [Extracted from the article]

Copyright of Clinical Oncology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)